Results 151 to 160 of about 25,080 (259)

Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy

open access: yesBMEMat, EarlyView.
Redox‐responsive lipid‐mimetic prodrug liposomes with high drug‐to‐lipid ratios enhance cabazitaxel delivery, prolong circulation, and enable tumor‐selective drug release for superior antitumor efficacy and safety. Abstract Liposomes represent one of the most extensively investigated nanocarriers in drug delivery.
Shengyao Xu   +16 more
wiley   +1 more source

Turning Bonding Into Function: The Emerging Role of the Bioactive Selenium─Metal Motif in Toxicology and Medicinal Chemistry

open access: yesChemistry – A European Journal, EarlyView.
Balancing Act: Se─M bond serving as the fulcrum of the balance scale to compare the different weight of toxicity and therapeutic effects in biological environment. ABSTRACT The synthesis and characterization of organo‐selenium compounds have attracted considerable interest for decades, driven by the search for efficient catalysts and bioinspired ...
Matteo Filippi   +6 more
wiley   +1 more source

Opsoclonus in Pediatric Patients: Differential Diagnosis and a Practical Approach to Evaluation

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Opsoclonus is an ocular dyskinesia characterized by involuntary, arrhythmic, multidirectional saccades. In pediatrics, opsoclonus is most commonly attributed to the rare neuroinflammatory disorder opsoclonus‐myoclonus‐ataxia syndrome (OMAS), typically considered a paraneoplastic syndrome associated with neural crest tumors. However, opsoclonus
Aubrey C. Reed   +5 more
wiley   +1 more source

Anesthesia-induced developmental neurotoxicity in the setting of systemic inflammation: the role of microglia. [PDF]

open access: yesExp Biol Med (Maywood)
Useinovic N   +6 more
europepmc   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy